Cerevel Gets FDA Fast-Track Designation for CVL-871 in Dementia-Related Apathy
June 15 2021 - 6:44AM
Dow Jones News
By Colin Kellaher
Cerevel Therapeutics Holdings Inc. on Tuesday said the U.S. Food
and Drug Administration granted fast-track designation to CVL-871,
in development for the treatment of dementia-related apathy.
The Cambridge, Mass., company, which is focused on neuroscience
diseases, said it plans to initiate screening in a Phase 2a
exploratory trial in dementia-related apathy in the next few weeks,
with data expected in the second half of 2022.
The FDA's fast-track program is designed to facilitate the
development and expedite the review of treatments for serious or
potentially life-threatening illnesses with high unmet medical
needs.
Cerevel said CVL-871 could be a potential treatment to address
the symptoms represented by dementia-related apathy, such as social
disengagement, diminished initiative and interest, and loss of
emotion.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 15, 2021 07:34 ET (11:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.